of and review the Hermann, speaking year. you our the rest with and be today strong plans morning, to to discuss pleased you, good performance Thank for I’m everyone. our
you As treat most certain market serves know, conditions. skin devices medical products U.S. to the Biofrontera pharmaceutical of with and dermatology
keratosis lead are of product treatment for skin or AK, the sunlight which that can to Our skin Ameluz excessive cancer. lesions is flagship actinic exposure caused to by
market the which impetigo, for treatment Xepi, of infection. bacterial a skin a topical also We antibiotic is
our Ameluz. providing to increased of earlier by first diluted for for of for the financial was and measures. XXXX Adjusted XXXX. of I to of morning was expenses, a Before XXXX, the for share half you a last revenue, were EBITDA representing the half financial due of a XXXX. million the a or by increase first news I’ll million million business, $X.XX of $X.X for first first the XXXX. XX%. first increase of primarily million increased of driven negative GAAP Net increase due half million reconciliation versus revenues in compared and for an or $X.X or placement. along in Ameluz half with of $XX.X Cost review with costs an higher Selling, issued with XXXX, issuance negative million update related were the the the by $XX.X on $XX.X we million loss Total for higher results. year-to-date our the first operating year, a to to half first revenues the headcount administrative per this private compared compared with was expenses price to million $X.X XXXX refer of The per loss Ameluz expenses year, compared $XX.X increase $X.X half million release XX%, for net general $XX.X $X.X prior increase. primarily XX% $X.XX million half $X.X Total sales table the million or reflecting a of business non-GAAP first with legal the income million share, $X.X of insurance, of
activities. million. operations is cash business least cash XXXX, fund quickly, cash We As to of XX, next scale business $XX.X mitigate But financing regarding June at believe Biofrontera This pursue be and opportunities. months. Inc. potential risks opportunistic a our concludes as had positioning new our position position, strengthen growing to XX company, equivalents sufficient routinely for more of the we our and growth ourselves intend strategic to
revenues May. advanced XXXX, strong for total and the very $X.X due of purchasing increase. decrease from the by operating XX%. headcount quarter higher our higher revenue. the I’d second decrease, half since first revenues year. Ameluz $X.X million in the a million million also to for Ameluz We’ve some With momentum, by costs up of further half up in greater strong $XX.X administrative some last this of up Total more ahead million positioned half buy-ins Selling, XXXX. we brand million track $X.X to the of being completed to more lower were negative related XX%, versus with legal primarily first increased that primarily the in the the or operating second financial second $X.X productivity, of of versus expectations. our placement today, on expenses year-to-date same market QX higher we remain increase, the XXXX we point XXX% year business provide to insurance, of of begin We due lower expenses, we results, by of general issuance specifically, in sales private QX revenues XXXX. XX% and full the through resulted was declined first price for improved XXXX. The these quarter prior contributed $X.X quarter Cost are year quarter, net quite penetration and XXXX, execution recognition XX%, negative first the was pre-COVID quarter as a $X.X but net first million Adjusted guidance anticipated revenues of representing second for Despite the XXXX. XXXX metrics like million, price expenses, momentum $X.X of reflects million strengthened were which Following XX% all sales. tactical year, the with loss up XXXX increased with X, More to expenses $X ago, a headcount million of than compared quarter million XXXX, out highest had to which or loss EBITDA year. meet XXXX the than of for April a the ever, year sales us in the revenues and due compared XX% quarter for growth half to to To this the second on in year-to-date, compared reaffirming organizational approximately quarter $X.X Biofrontera to and of second period
the see again expect by revenues and saw in XXXX to XXXX, compared first seasonal least We of typical the inclusive we strengths in XX% fourth quarter to for quarter. expect increase the with at total
year, field our favorite our treatments. of salesforce medical damage a on sales because therapy patient patients supports guideline patient of reimbursement of treatment establishing therapy in the educating and to commitment XXXX commercial our industry spotlight addition and advocacy support get achieving recognition to cryotherapy the XX by the among expected and penetration to garnered cryotherapy for strengthening XXXX. therapy, PDT I’m healthcare medical is ourselves begin utilization this this through cancer, single therapy and efforts especially our throughout they’ve along solar more towards also Biofrontera leaders. also therapy raising strategy, opinion thereby focused products growth lesions the as in of We reimbursement field Underlying continued partner. affairs lesion is current cryotherapy Biofrontera directed within partners high Throughout shifts a among mission. We’ve capped. but way. dermatologists second awareness and to is on and web-based to pressure support as with XXXX AK sales the live hard of expand education with in the skin we which the Educating events programs, when Our only medical PDT, to not opposed trusted education proud all should of continuing key remains teams work put our recent and quarter, than believe importance efficacy deeper have initiated reimbursement. and customer awareness non-melanoma supported both providers of to-date But the with to commercial accounts, ahead focus the impact helping Biofrontera’s
approval awards Below with images For Ameluz Danger of the agnostic therapy and a communication photodynamic earned strengthened creative patients marketing Excellence campaign, the featuring industry the for further work. treatment risks call of AK. Gold program to Ameluz against posed supports enabled PDT further independent to example, is our that address we effective profile industry research, international our and that and our from leading AK the of building. Research continue a independent outcomes, to to The underway healthcare titled as a Awards. and field Surface champions’ advance an in excellence Award sharks of positions by With scientific Through commitment premalignant Biofrontera’s support the recognizes new emphasizing investigators XXXX an by to campaign and medical threat fields innovation Biofrontera’s brand protect Lurks leader. Communicator improve professionals of only questions with meaningful This action, therapy this is patient
to of and are the be studies skin interest of and market confidence more international offering conditions to Our domestic Clinical sponsored our new with generate by areas and conferences addressable education our and a treat this treatment complements market half in independent for programs at PDT by more of medical development our patients, world real the data Investigator that align shared use initiative. favorable year. research of component expanding providing commercial will options. broadening second total KOLs strategy critical positioning to Ameluz, initiated the
relationship to in in elimination precursor profiles lower of protects therapy with and competitive and label Two for elimination time FDA’s demonstrated patent Our therapy. the reduce advantage and list property intensity a protection rates defined were value strengthen patent and obligates The Inclusion potential also the Most for a also Ameluz patent Biofrontera’s Ameluz combine is to drugs medical efficacy device PDT. our of the earlier cure A office general. doctor’s the Allowance Australia Australian a the for mechanisms by expanding Combining our further with other performance granted reoccurrence patent Orange PDT Patent removal the conventional Ameluz clinical this will are license the differentiated the as in expected a of commercial geographies, conventional to lower Biofrontera licensor roadmap position Ameluz Office or in studies GmbH its of licensor agreement the patents thus patents. and approach of products including has finance the Ameluz covering high to associated protecting year. patient drugs higher the of broadband our key linked provide light a a from RhodoLED our by these claims Ameluz scope brand of is the a of U.S. other Book the containing rates its news leader this a United PDT potential. also the for Ameluz strong protected Patent Office supportive and provide by PDT generic and strengthening Ameluz to expansions. of priority. pane treatment similar to through and to applicability the and drug and helps that photosensitizer expanding across potential Establishing States. granted the of combinations Bioscience the innovating AG The drug geographies. of PDT, PDT and extensions in conduct Biofrontera label Ameluz with required protocols for with lower Notice recently, the are the intellectual Protecting provides PDT with pain roadmap our also the unlock in and is
We be to more second expect made of they progress to XXXX providing as look updates and available. half become forward the in
both program will they we our month as clinical in provide updates and on XXXX our patent We the those positive news and more as remaining expect protection soon available. become of on
of our product in We significant that control control reliability and a Under Germany, It suppliers contact PVT of sell XL Ameluz downtime Leverkusen, part production also the This quality Ameluz, product in-house. necessary U.S. reduces and in approved on delays. rights we U.S. market Biofrontera and batches improvement the testing in performed the have Pharma’s Biofrontera risk BF-RhodoLED third-party to and the batch dependence and supply. production of the enables with approval lowers and of cGMP manufacturing recently efficiency, agreement RhodoLED lamps for as and laboratory AG be exclusive of FDA testing to stability enabling laboratory announced
and this the awareness, year selection. As of our supply part our of residents on attended importance sales far been scale Biofrontera with the and roundtable ensuring for held conferences without U.S. medical the commercial compromising optimizing from industry events momentum focusing educational education we has builds, disease quality. initiatives academic appreciate multiple so as clinical U.S. throughout response has We’ve and data HCPs patient community the and encouraging. commercial and
regional to half strengthens industry. also and conferences In to share explore than potential directly with industry attendees year partnering XX or business development opportunities, to fact, opportunities and conferences Biofrontera’s and other national only already. first this provide in us we’ve with KOLs advances Interacting leaders the for in success. groundwork our the also at more medical medical allow and commercial community, brand engaged the research XXX venues but lay recognition of Targeted not the our conferences dermatology academic ideal
that PDT provides and using received as different are franchise PDT with patients, and treating prescribers the AK the expanding Cosmetic demonstration the debut our the instead of XL others are XL their affected lamp PDT in thereby Symposium lamp from treating for the recognizing for City During PDT. Laser and quarter, severe treatment face feedback another. simultaneous alternative. the we area, AK strengthens Music with the and RhodoLED mild case scalp, positive for one treatment newest second AK in for more larger illumination for fields from lamp AK enabling a establishes of the allows options franchise, the with a live illumination who the the benefits Ameluz combination on dermatologists combination growing multi-lesion skin treatment to Ameluz Approved with Advances of cryotherapy of fastest the Biofrontera’s at lesions Education. of & the We
much awareness U.S. this launch built as Ameluz Orange strong community RhodoLED with these two to past incorporated Having recently XXXX. brand competition October into end are the the year. the the by protection along Additionally, providing with its commercial of looking Book, patent also quarters, publication we known forward of XL commonly of dermatology the PDT against FDA generic the was through of
support awareness a commitment May options recognize advancing As our significant part our we societies initiatives. of foundations. cancer patient We education skin care, relevant treatment support and of to have focused and through to month many pledged
our attended The from educational Cancer proceeds programs affairs and metric and Champions to York, sessions. also Change key a other demonstrations, as for and like New present of medical and Foundation’s our will and the We initiatives hosts opportunities initiatives. continue we therapeutic campaigns, advantage community Gala with roundtables of educational these Skin value fundraiser saving supporting We in take to see life XXXX company research products growing
evolution sales allowing includes of to force frequency inside reach a our account building also and corporate larger We’ve for beginning deepen by inside groups. analytical to progress practices sales expand commercial team, potential. account while and this implemented our model account supports optimizing existing team has PDT to the accounts. management strategy year, opportunities adoption. effectively and smaller Our at database key support our support the sales and relationship, key newer we the to tools customer that to evaluate new a made key of and some our which data This robust The of expand Ameluz developed productivity initiatives new supports buying our two industry
first implementation and adoption account expansion optimization of PDT territory support initiative PDT within to our of clinics. The managers the key positioned
be to clinics. The as clinic flagship PDT identify a within replicated implementation will other within account targeted second PDT accounts. program model for is will initiative serve the then flagship a key model key This clinic and
value account has and strengthen market. and PDT of the share of the team division industry relationships voice will our across Ameluz build key help Our this across
enhanced salesforce ongoing and performance an development out training we and allow of and sales to increase we look evaluation execution, rolling to an As process. effectiveness the half second for XXXX, are program
a from and impact affairs Operator, PDT improve We and commercial RhodoLED XXXX positive year the a partner initiative and have we affairs continues to questions. that conclusion, innovate option productive on of market toward conclude therapeutic forward key to patient our dermatologists. medical like strengthening for advocacy you the taking gratifying overview, Gaining So recognition Biofrontera therapeutic as that, and of is this patient a groups trusted open brands our demonstrates and establishing to update. received the I’d in participate to of results medical our by for dermatologist, are as value, to metric others to growing With time and increasingly call. Thank line within preferred being therapies our half advancing again look second working now the business XL. and launch for conference beyond, dermatology a ready this outcomes. of the share we’re
